SMMT Investors Have Opportunity to Lead Summit Therapeutics Inc. Securities Fraud Lawsuit with the Schall Law Firm

Core Viewpoint - A class action lawsuit has been filed against Summit Therapeutics Inc. for alleged violations of securities laws related to misleading statements about its drug study results [1][4]. Group 1: Lawsuit Details - The lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - Investors who purchased securities between March 17, 2022, and September 22, 2022, are encouraged to participate in the lawsuit [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against the Company - The complaint alleges that Summit Therapeutics made false and misleading statements regarding the results of its Pinnacle Study of poziotinib, a treatment for lung cancer [4]. - The misleading public statements caused investors to suffer damages once the truth about the company's situation was revealed [4].